RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising new combo therapy targets hard-to-treat lymphoma
Disease control OngoingThis study tests a new treatment for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior therapy. The treatment combines two drugs (tafasitamab and lenalidomide) with standard chemotherapy, followed by a stem cell t…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill combo aims to tackle tough lymphoma when other treatments fail
Disease control OngoingThis study tests whether adding the oral drug selinexor to standard chemotherapy (R-GDP) can help people with relapsed or refractory diffuse large B-cell lymphoma who cannot receive a stem cell transplant or CAR-T therapy. About 500 participants will receive either selinexor at o…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy hopes to tackle tough lymphoma
Disease control OngoingThis trial tests two new drug combinations (glofitamab plus atezolizumab or polatuzumab vedotin) in adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The study aims to find the safest dose and see if these combos shrink tumors. About 2…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC